Authors
Hakar Abdulkareem Saeed, Nidhal Abdulkader Mohammed Ali, Ramadhan Tayeb Othman
Published in
Future science OA. Volume 12. Issue 1. Pages 2741250. Epub Oct 06, 2026.
Abstract
To evaluate whether dapagliflozin attenuates early cardiac functional and biomarker changes during anthracycline-based chemotherapy.
In this randomized, double-blind, placebo-controlled phase II trial, 94 adults were assigned 1:1 to dapagliflozin 10 mg once daily or placebo for 4 months; 90 completed follow-up. The primary endpoint was 4-month left ventricular ejection fraction (LVEF), analyzed using analysis of covariance (ANCOVA) adjusted for baseline LVEF. Secondary and exploratory outcomes included cardiac biomarkers and the early-to-late transmitral flow velocity ratio (E/A ratio).
Dapagliflozin was associated with higher adjusted 4-month LVEF than placebo (adjusted mean difference, 2.40 percentage points; 95% confidence interval [CI], 1.25-3.54; p < 0.001). Change in LVEF was +0.13 ± 2.28 versus -2.31 ± 3.27 percentage points, respectively. E/A ratio decline was attenuated (p = 0.030). Galectin-3 decreased with dapagliflozin but increased with placebo (p < 0.001), while N-terminal pro-B-type natriuretic peptide (NT-proBNP) increased less (p = 0.004). No major safety signal was observed during the 4-month follow-up.
Dapagliflozin was associated with attenuation of early anthracycline-associated cardiac functional and biomarker changes. Larger, longer trials are needed to determine clinical benefit.
www.clinicaltrials.gov identifier is NCT06888505. Retrospectively registered.
PMID:
42836855
Bibliographic data and abstract were imported from PubMed on 06 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0